Patent · US Active

ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

US9212227B2 · kind B2 · utility

12Cited by

3References

15Claims

0Family size

Assignee

JANSSEN BIOTECH, INC. · US

Inventors

Karen Duffy · Spring House, US
Natalie Fursov · Spring House, US
LeRoy Hall · Raritan, US
Catherine Healy · Spring House, US
Roberta Lamb · Lansdowne, US
Jinquan Luo · Malvern, US
Ravi Malaviya · Spring House, US
Michael Naso · Union, US
Michael Pratta · Glassboro, US
Mark Tornetta · Collegeville, US
John Wheeler · Spring House, US
Sheng-Jiun Wu · Broomall, US

Key dates

Filing date	Mar 13, 2013
Grant date	Dec 15, 2015
Priority date	—
Expiry date	Mar 13, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.